Menu
1 min read · estimated
APPROVED USE
What FDA approved
Single-agent treatment for adults with unresectable or metastatic esophageal squamous cell carcinoma after systemic chemotherapy that did not include a PD-1 or PD-L1 inhibitor.
LAMPGEN ANALYSIS
Why it matters
The initial U.S. approval added another checkpoint inhibitor for the specified previously treated esophageal cancer population.
What research teams should watch
Confirm squamous histology and reconcile all prior checkpoint exposure before applying this historical indication.
PRIMARY RECORDS